Loading quotes...

Forecast

The analysts' average price target is €24.69 (+55.77%). The median is €24.69 (+55.77%).

Buy	12
Hold	5
Sell	2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Omeros benefits from Yartemlea launch after FDA approval and beats quarterly expectations

Omeros reported adjusted earnings of $0.02 per share and net revenue of $28.5 million for the second quarter, well above expectations. The main driver was the commercial launch of the FDA‑approved antibody Yartemlea for the treatment of TA‑TMA, giving the company a monopoly position. Omeros also generated positive operating cash flow of $4.1 million. » More on finanzen.net
Omeros reaches 52-week high of $18.16 after strong quarterly results

Omeros shares rose to a new 52-week high of $18.16, lifting market capitalization to around $1.31 billion. In the second quarter the company comfortably beat analysts’ expectations with adjusted earnings of $0.02 per share and revenue of $28.5 million, supported by the launch of YARTEMLEA. Data from InvestingPro point to an overbought RSI level and a possible overvaluation of the stock. » More on de.investing.com
Omeros beats Q2 forecasts thanks to YARTEMLEA, stock rises 20%

Omeros reported adjusted earnings of $0.02 per share and revenue of $28.5 million for Q2 2026, well above consensus estimates. Gross product revenue from YARTEMLEA was $32.2 million in the first full quarter of launch and contributed materially to positive operating cash flow of $4.1 million. Management expects higher selling and R&D expenses in Q3 but provided no revenue guidance; the stock rose about 20% in after-hours trading. » More on de.investing.com
Omeros receives negative CHMP opinion on narsoplimab, will seek reconsideration

After an oral explanation meeting the CHMP adopted a negative opinion on Omeros' narsoplimab marketing application. Omeros plans to request reconsideration and an assessment by an EMA Ad Hoc Expert Panel. H.C. Wainwright cut its price target from $40 to $33 but kept a Buy rating, citing the U.S. launch as the key value driver. » More on finance.yahoo.com
Omeros announces repurchase of convertible notes of up to $16 million

Omeros has entered privately negotiated agreements to repurchase its 9.50% convertible notes due 2029 with a principal amount of up to about $16 million; the total purchase price including interest is expected to be up to about $34 million and will be partly determined by the share price during an upcoming averaging period. The repurchases are expected to settle between July 6 and 16; if fully repurchased, about $54.8 million in principal would remain outstanding. At the same time, Omeros significantly missed expectations for revenue and EPS in Q1 2026, while H.C. Wainwright remains at a buy rating with a $40 price target and highlights key data releases due mid‑2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Omeros Co. has already paid €0.94 in dividends. The last payout was in May 2022.

Financials

In the last quarter, Omeros Co. had revenue of €25m and net profit of €11.59m

(EUR)	June 2026	YoY
Revenue	25m	-
Gross profit	24.3m	378.24%
Net profit	11.59m	153.75%
EBITDA	12.66m	158.10%

Fundamentals

Metric	Value
Market capitalization	€1.12bn
Number of shares	72.39m
52-week high/low	€19.07 - €5.60
Dividends	No
Beta	2.57
P/E ratio	9.01
PEG ratio	0.00
P/B ratio	-24.16
P/S ratio	32.41

Company profile

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.